Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Health & Science
Recent news which mentions Health & Science
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
32
33
Next >
Mpox vaccine maker Bavarian Nordic seeks ‘critical’ EU approval for teens after WHO declares health emergency
August 16, 2024
Tags
Health & Science
Pharmaceuticals
Health care industry
From
CNBC.com News
What's next for the Biden administration's Medicare drug price negotiations
August 15, 2024
Tags
Merck & Co Inc
Pharmaceuticals
Companies
From
CNBC.com News
Health stocks jump as WHO declares mpox global health emergency
August 15, 2024
Tags
Biotechnology
Biotech and Pharmaceuticals
Emergent BioSolutions Inc
From
CNBC.com News
Biden administration to release prices for first 10 drugs subject to landmark Medicare negotiations
August 15, 2024
Tags
Novo Nordisk A/S
Biotech and Pharmaceuticals
Politics
From
CNBC.com News
Healthy Returns: Eli Lilly gains momentum against Novo Nordisk in the weight loss drug market
August 14, 2024
Tags
Health & Science
Health care industry
Biotech and Pharmaceuticals
From
CNBC.com News
Digital health company Ro launches GLP-1 insurance-coverage checker to help patients navigate costs
August 13, 2024
Tags
Breaking News: Business
Business
Health & Science
From
CNBC.com News
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
August 08, 2024
Tags
Biotech and Pharmaceuticals
Earnings
Business News
From
CNBC.com News
CVS slashes profit outlook on higher medical costs, says top Aetna executive will leave
August 07, 2024
Tags
Earnings
Biotech and Pharmaceuticals
Elevance Health Inc
From
CNBC.com News
Wegovy maker Novo Nordisk posts earnings miss, cuts operating profit outlook
August 07, 2024
Tags
Health care industry
Medicine
Europe Markets
From
CNBC.com News
Healthy Returns: What drugmakers are saying about final negotiated prices with Medicare
August 06, 2024
Tags
Biotech and Pharmaceuticals
Abbvie Inc
Politics
From
CNBC.com News
Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA says
August 02, 2024
Tags
US: News
Eli Lilly and Co
Biotechnology
From
CNBC.com News
Your health records are coming to new apps. Here's why
August 01, 2024
Tags
Enterprise
Internet
US: News
From
CNBC.com News
Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage study
August 01, 2024
Tags
Biotech and Pharmaceuticals
Science
Novo Nordisk A/S
From
CNBC.com News
Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction
August 01, 2024
Tags
Biotechnology
Breaking News: Earnings
US: News
From
CNBC.com News
Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market
August 01, 2024
Tags
Earnings
Biotech and Pharmaceuticals
Business News
From
CNBC.com News
23andMe CEO files proposal to take company private as stock craters
July 31, 2024
Tags
Health & Science
Mobile
23andMe Holding Co/
From
CNBC.com News
Healthy Returns: Here’s what GLP-1s are being tested for beyond weight loss, diabetes
July 31, 2024
Tags
Science
Augmedix Inc
Biotech and Pharmaceuticals
From
CNBC.com News
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
July 30, 2024
Tags
Science
Eisai Co Ltd
Biotech and Pharmaceuticals
From
CNBC.com News
Neuralink rival Synchron lets patients control Apple Vision Pro with their thoughts
July 30, 2024
Tags
Health & Science
Breaking News: Business
Apple Inc
From
CNBC.com News
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
July 30, 2024
Tags
US: News
Eli Lilly and Co
Biotechnology
From
CNBC.com News
Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs
July 30, 2024
Tags
US: News
Breaking News: Earnings
Dividends
From
CNBC.com News
Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
July 30, 2024
Tags
Biotech and Pharmaceuticals
Earnings
Health care industry
From
CNBC.com News
Dexcom shares plunge more than 40%, head for worst day on record
July 26, 2024
Tags
Social media
Dexcom Inc
US: News
From
CNBC.com News
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
July 26, 2024
Tags
Companies
Pharmaceuticals
Health & Science
From
CNBC.com News
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
July 26, 2024
Tags
Business News
Health care industry
Breaking news
From
CNBC.com News
Dexcom shares plummet more than 30% after company lowers fiscal year guidance
July 25, 2024
Tags
Enterprise
Earnings
Breaking News: Technology
From
CNBC.com News
Viking Therapeutics stock jumps 16% after drugmaker moves weight loss injection to late-stage trial
July 25, 2024
Tags
Breaking news
Health care industry
Business News
From
CNBC.com News
GE HealthCare taps Amazon Web Services to build generative AI for medical use
July 25, 2024
Tags
Health care industry
Breaking News: Technology
Media
From
CNBC.com News
India is on alert after a fresh outbreak of the deadly Nipah virus. Here’s what you need to know
July 25, 2024
Tags
Health care industry
Health & Science
World News
From
CNBC.com News
Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
July 24, 2024
Tags
Biotechnology
US: News
Breaking News: Business
From
CNBC.com News
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.